Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cidara Therapeutics

22.39
+0.81003.75%
Post-market: 22.390.00000.00%19:20 EDT
Volume:77.39K
Turnover:1.71M
Market Cap:245.25M
PE:-0.84
High:22.64
Open:21.81
Low:21.50
Close:21.58
Loading ...

Company Profile

Company Name:
Cidara Therapeutics
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
38
Office Location:
6310 Nancy Ridge Drive,Suite 101,San Diego,California,United States
Zip Code:
92121
Fax:
- -
Introduction:
Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Directors

Name
Position
Jeffrey Stein
Director,President and Chief Executive Officer
Scott Rocklage
Director and Chairman
Chrysa Mineo
Director
Daniel D. Burgess
Director
Theodore R. Schroeder
Director
Timothy R. Franson
Director

Shareholders

Name
Position
Jeffrey Stein
Director,President and Chief Executive Officer
Paul Daruwala
Chief Commercial Officer and Chief Operating Officer
Matthew Onaitis
Chief Financial Officer and General Counsel
Neil Abdollahian
Chief Business Officer
Taylor Sandison
VP-department